Goldman Sachs
EVMN icon

Goldman Sachs’s Evommune Inc EVMN Stock Holding History

Goldman Sachs’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.56M Buy
192,995
+38,672
+25% +$898K ﹤0.01% 4474
2026
Q1 		$3.55M Buy
154,323
+92,648
+150% +$2.09M ﹤0.01% 4019
2025
Q4 		$1.06M Buy
+61,675
New +$1.16M ﹤0.01% 5099

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $863M AUM 26.03% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Goldman Sachs's EVMN Position: Q2 2026 in Review

Goldman Sachs increased its Evommune Inc (EVMN) stake by 25% in Q2 2026, buying an estimated $898K and bringing the position to 192,995 shares worth $2.56M. The position accounts for ﹤0.01% of the portfolio, ranked #4474.

Goldman Sachs first reported a position in EVMN in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.55M in Q1 2026. 105 funds tracked by Wall St. Rank hold EVMN as of Q2 2026.

  • Goldman Sachs held 192,995 shares of Evommune Inc worth $2.56M as of Q2 2026.
  • Goldman Sachs bought 38,672 Evommune Inc shares in Q2 2026, an estimated $898K.
  • Evommune Inc made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #4474 holding.
  • Goldman Sachs first reported a position in Evommune Inc in Q4 2025 and has held it in 3 quarters since.
  • Goldman Sachs's Evommune Inc position peaked at $3.55M in Q1 2026.
  • 105 funds tracked by Wall St. Rank held Evommune Inc as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.